Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | TNNI3 | P19429 | 1/20 | 0.49 |
| ▸ | TNNT2 | P45379 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18152943 | 0.89 | RAB9A (0.51) | ALDH1A1SMN1; SMN2POLBCYP1A2MAPT | |
| SCHEMBL377804 | 0.87 | MYC (0.58) | ALDH1A1SMN1; SMN2TDP1HSD17B10POLB | |
| SCHEMBL29229375 | 0.85 | ALDH1A1 (0.54) | ALDH1A1SMN1; SMN2TDP1HSD17B10TP53 | |
| SCHEMBL5327455 | 0.84 | SMN1; SMN2 (0.71) | ALDH1A1SMN1; SMN2TDP1HSD17B10POLB | |
| SCHEMBL13206915 | 0.82 | RAB9A (0.42) | ALDH1A1SMN1; SMN2POLBCYP1A2MAPT | |
| SCHEMBL7902882 | 0.82 | ALDH1A1 (0.51) | ALDH1A1SMN1; SMN2TDP1HSD17B10POLB | |
| SCHEMBL2336203 | 0.82 | POLB (0.68) | ALDH1A1SMN1; SMN2TDP1HSD17B10POLB | |
| SCHEMBL29990241 | 0.82 | POLB (0.68) | ALDH1A1SMN1; SMN2TDP1HSD17B10POLB | |
| SCHEMBL31661220 | 0.81 | ALDH1A1 (0.63) | ALDH1A1SMN1; SMN2TDP1HSD17B10TP53 | |
| SCHEMBL533801 | 0.81 | SMN1; SMN2 (0.69) | ALDH1A1SMN1; SMN2TP53POLBCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2074114-B1 | PYRIMIDINONES AS CASEIN KINASE II (CK2) MODULATORS | EXELIXIS INC (US) | 2013-03-06 | — | — | EP | disclosed |
| US-8324231-B2 | Pyrimidinones as casein kinase II (CK2) modulators | EXELIXIS, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-8324231-B2 | Pyrimidinones as casein kinase II (CK2) modulators | EXELIXIS, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-8324231-B2 | Pyrimidinones as casein kinase II (CK2) modulators | EXELIXIS, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-8299055-B2 | 8-substituted isoquinoline derivative and the use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-10-30 | — | — | US | disclosed |
| US-8242129-B2 | 6-phenylpyrimidinones as PIM modulators | EXELIXIS, INC. (US) | 2012-08-14 | — | — | US | disclosed |
| US-8242129-B2 | 6-phenylpyrimidinones as PIM modulators | EXELIXIS, INC. (US) | 2012-08-14 | — | — | US | disclosed |
| US-8242129-B2 | 6-phenylpyrimidinones as PIM modulators | EXELIXIS, INC. (US) | 2012-08-14 | — | — | US | disclosed |
| EP-2366699-A1 | 8-SUBSTITUTED ISOQUINOLINE DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2011-09-21 | — | — | EP | disclosed |
| US-20100261701-A1 | 8-Substituted isoquinoline derivative and the use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-10-14 | — | — | US | disclosed |
| US-7317026-B2 | Sleep disorders; side effect reduction ; antihistamine antagonist | HYPNION, INC. (US) | 2008-01-08 | — | — | US | disclosed |
| US-7317026-B2 | Sleep disorders; side effect reduction ; antihistamine antagonist | HYPNION, INC. (US) | 2008-01-08 | — | — | US | disclosed |
| WO-2007138472-A2 | TRIAZOLOPYRIDAZINE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007064227-A1 | MULTIMERIC MAGENTIC RESONANCE CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2007-06-07 | — | — | WO | disclosed |
| WO-2007064227-A1 | MULTIMERIC MAGENTIC RESONANCE CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2007-06-07 | — | — | WO | disclosed |
| US-7189757-B2 | Treatment of sleep disorders using CNS target modulators | HYPNION, INC. (US) | 2007-03-13 | — | — | US | disclosed |
| US-7189757-B2 | Treatment of sleep disorders using CNS target modulators | HYPNION, INC. (US) | 2007-03-13 | — | — | US | disclosed |
| US-5374628-A | Aryl and heteroaryl(phosphinylmethyl)phosphonate squalene synthetase inhibitors and method | E. R. SQUIBB & SONS, INC. (US) | 1994-12-20 | — | — | US | disclosed |
| US-5278153-A | Hypocholesterolemic or hypolipemic | E. R. SQUIBB & SONS, INC. (US) | 1994-01-11 | — | — | US | disclosed |
| EP-0570706-A1 | Aryl and heteroaryl (phosphinylmethyl) phosphonate squalene synthetase inhibitors and method | E.R. SQUIBB & SONS, INC. (US) | 1993-11-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261701-A1 | 8-Substituted isoquinoline derivative and the use thereof | RELA, NFKBIA, NFKB2 | ALDH1A1 1380/4885SMN1; SMN2 3014/4885TDP1 1331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.